Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01560195CT.gov A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy | — | Unknown | — | — | — |
NCT01611051CT.gov A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT02119715CT.gov A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neutropenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Regramostim (this asset) | Jiangsu HengRui Medicine Co., Ltd. | P3 | BB · 64 |
| f-627 | EVIVE Biotechnology | P3 | BBB |
| Pegfilgrastim | Affiliated Hospital of North Sichuan Medical College | P4 | BBB |
| Nivestim | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P4 | BBB |
| Cefepime | Hospital Universitari Vall d'Hebron Research Institute | P4 | BB |
| Docetaxel | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Cyclophosphamide | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Spi-2012 | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Posaconazole | Merck Sharp & Dohme LLC | P4 | BB |
+42 more in the Neutropenia cohort
Other indications for Regramostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 67 |
| Lymphoma | — | P4 | B · 60 |
| Prostate Cancer | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Regramostim in Neutropenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/regramostim-neutropenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →